evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

41 questions · 42 findings · 3 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 4.8%GRADE not reported 0 · 0%Very low 12 · 28.6%Low 15 · 35.7%Moderate 11 · 26.2%High 2 · 4.8%

Heparin prophylaxis vs no prophylaxis

All‐cause mortality

Heparin prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).

2 findings from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

All‐cause mortality (time‐to‐event) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Recurrent venous thromboembolism (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Recurrent venous thromboembolism · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Major bleeding · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in major bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Minor bleeding (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Thrombocytopenia (main analysis‐ active cancer) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in thrombocytopenia (main analysis‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

All‐cause mortality · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Recurrent VTE · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis may leads to lower recurrent VTE compared with low molecular weight heparin secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major bleeding · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major GI bleeding · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in major GI bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major upper GI bleeding · patients with cancer with venous thromboembolism

It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major upper GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major lower GI bleeding · patients with cancer with venous thromboembolism

It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major lower GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).

1 finding from 1 review

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major non‐GI bleeding · patients with cancer with venous thromboembolism

It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major non‐GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).

1 finding from 1 review